 |
 |

Clinical Aspects of Chronic Hepatitis C Infection
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: Dr Flamm1 briefly addressed the question of whether medication should be discontinued early in patients with HCV who do not respond early to treatment. Early virologic response, defined as a minimum 2 log decrease in viral load during the first 12 weeks of treatment, is predictive of sustained virologic response.2 Flamm recommended stopping treatment if quantitative HCV-RNA titers do not decline by more than 2 logs by week 12 of therapy, in patients infected by either genotype 1, 2, or 3. Patients with genotype 1 who fail to achieve an early response at week 12 of treatment have only a small chance of achieving a sustained response even if therapy is continued for a full year.3 However, patients infected by genotype 2 or 3 have a high probability of a sustained response.3 Thus, viral-RNA quantification at 12 weeks does not seem warranted in either of these situations. . . . [Full Text of this Article]
Hakan Leblebicioglu, MD
Department of Infectious Diseases and Clinical Microbiology Ondokuz Mayis University Medical School Samsun, Turkey
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Clinical Aspects of Chronic Hepatitis C Infection
Ajit Singh Kashyap, Kuldeep Parkash Anand, and Surekha Kashyap
JAMA. 2003;290(11):1452.
EXTRACT
| FULL TEXT
Clinical Aspects of Chronic Hepatitis C Infection
Ami Schattner and Hilla Knobler
JAMA. 2003;290(11):1453.
EXTRACT
| FULL TEXT
Clinical Aspects of Chronic Hepatitis C InfectionReply
Steven L. Flamm
JAMA. 2003;290(11):1453-1454.
EXTRACT
| FULL TEXT
Chronic Hepatitis C Virus Infection
Steven L. Flamm
JAMA. 2003;289(18):2413-2417.
EXTRACT
| FULL TEXT
|